News | Vascular Access | November 07, 2019

Early Bird Bleed Monitoring System Used in First Commercial U.S. Patient

Novel technology offers physicians first and only real-time detection and monitoring of endovascular bleed complications

The Saranas Early Bird Bleed Monitoring System offers real-time detection and monitoring of transcatheter intervention vascular access site bleed complications.

The Saranas Early Bird Bleed Monitoring System offers real-time detection and monitoring of transcatheter intervention vascular access site bleed complications.

November 6, 2019 — Saranas Inc. announced completion of the first U.S. commercial case using its Early Bird Bleed Monitoring System for real-time detection and monitoring of endovascular bleed complications. Robert Kipperman, M.D., co-director of the Structural Heart Disease Program at Morristown Medical Center, and Bledi Zaku, M.D., cardiothoracic surgeon, successfully used the Early Bird to monitor for bleed complications during a transcatheter aortic valve replacement (TAVR) procedure conducted at the Gagnon Cardiovascular Institute, Morristown Medical Center in Morristown, New Jersey.

“We are excited to be the first program worldwide to incorporate the use of the Early Bird into our endovascular cases,” Kipperman said. “The Early Bird device was easily integrated into our standard workflow and provides meaningful information to secure and optimize patient outcomes.”

The Early Bird addresses a large and growing unmet need. One in five patients experience a bleeding complication during large-bore endovascular procedures, such as TAVR, endovascular aneurysm repair (EVAR) and percutaneous hemodynamic support. Further, a 2017 report in the Journal of the American Medical Association (JAMA) reported a three times increase in mortality, two times increase in length of stay and 60 percent increase in healthcare costs due to these type bleeding complications.[1]

The Early Bird Bleed Monitoring System includes a bleed detection array with integrated electrodes in a fully functional vascular access sheath. The device is designed to measure changes in bioimpedance to detect and monitor bleeding from vessel injury during endovascular procedures where the femoral artery or vein is used to obtain vascular access. Visual and audible indicators on the Early Bird notify the clinician of the onset and progression of bleeding events.

“The Early Bird is a transformative technology that provides physicians with the ability, for the first time, to effectively monitor the bleed status of the patient during and post endovascular procedures, receive timely notifications of actual bleeds and potentially reduce the severity of bleeding complications,” explained Philippe Généreux, M.D., chief medical officer at Saranas. “Compared to the current paradigm of waiting for symptoms, which could take hours to develop, the Early Bird allows physicians to detect bleeding in real-time and take the necessary actions quickly to protect the outcomes of the procedure and aid recovery for the patient.”

Watch an interview with Généreux in the VIDEO: How to Achieve Hemostasis With Large Bore Device Access.

Saranas was granted de novo classification by the U.S. Food and Drug Administration (FDA) for the Early Bird in March 2019. The company presented first-in-human results in May 2019 at the Society for Cardiovascular Angiography Interventions (SCAI), demonstrating that the Early Bird Bleed Monitoring System is safe, easily incorporated into standard workflows and able to detect bleeding before progression to a more severe or symptomatic phase. Read more about the SCAI presentation.

For more information: www.saranas.com

 

Reference: 

1. Björn Redfors, Brendan M. Watson, Thomas McAndrew, et al. Mortality, Length of Stay, and Cost Implications of Procedural Bleeding After Percutaneous Interventions Using Large-Bore Catheters. JAMA Cardiol. 2017;2(7):798-802. doi:10.1001/jamacardio.2017.0265.

 

Related Content

Patients undergoing cardiac catheterization are traditionally instructed to follow nothing by mouth, or nil per os (NPO), as there are no current standardized fasting protocols, but the CHOWNOW study found patients do not need to fast and will have similar outcomes. #SCAI2020
Feature | Cath Lab | May 18, 2020
May 18, 2020 – Patients undergoing cardiac catheterization are traditionally instructed to follow nothing by mouth, o
htisham Mahmud, M.D., FSCAI, president of the Society for Cardiovascular Angiography and Interventions (SCAI) and chief, Division of Cardiovascular Medicine at UC San Diego Medical Center,
Podcast | Cath Lab | May 13, 2020
This podcast is an interview with Ehtisham Mahmud, M.D., FSCAI, president of the Society for Cardiovascular Angiograp
Nuance Communications Inc. introduced Nuance Cardiovascular CAPD, a new computer-assisted physician documentation (CAPD) solution designed to help cardiologists improve the quality of complex documentation and the accuracy of reimbursement for cardiac catheterization procedures. The Nuance Cardiovascular CAPD solution is available through a partnership with ZHealth for this solution, which is based on patented algorithms built with ZHealth’s interventional documentation and coding expertise.
News | Cath Lab | January 31, 2020
January 29, 2020 – Nuance Communications Inc.
Videos | Cath Lab | January 09, 2020
Haval Chweich, M.D., medical director of the cardiac critical care unit (CCU) at Tufts Medical Center, and assistant...
People watch the live presentation of the five-year EXCEL Trial data by Gregg Stone, M.D., in the Abbott booth at TCT 2019. Abbott makes the Xience stent used in the trial, which compared equally with long-term CABG surgical outcomes.  In early December 2019, leaders of the European Association for Cardiothoracic Surgery (EACTS) withdrew their support for European practice guidelines that endorse the use of coronary stents in many patients with left main coronary artery disease.

People watch the live presentation of the five-year EXCEL Trial data by Gregg Stone, M.D., in the Abbott booth at TCT 2019. Abbott makes the Xience stent used in the trial, which compared equally with long-term CABG surgical outcomes.

News | Cath Lab | January 02, 2020 | Dave Fornell, Editor
January 2, 2020 — In early December 2019, leaders of the European As...
News | Cath Lab | December 18, 2019
December 18, 2019 — Cook Medical initiated a recall of its CrossCath Support Catheters in November, which the U.S.